ArticleJournal of cancer research and clinical oncology2025
Comprehensive analysis based on spatial domains identifies CD44 as a potential target of puerarin.
Article in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comparative In Vitro Response of HaCaT and A375 Melanoma Cells to Zinc Oxide Nanoparticles Synthesized Using Puerarin.Journal of xenobiotics · 2026Article
- Plant-Derived Bioactive Compounds and Their Therapeutic Potential in Cancer.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundMelanoma, a highly metastatic and treatment-resistant malignancy, urgently requires novel therapeutic strategies. Puerarin, a natural isoflavone with established anti-tumorigenic effects in diverse cancers, remains underexplored in melanoma despite its potential to modulate melanogenesis and oxidative stress. This study investigates puerarin's spatial targeting mechanisms in melanoma to elucidate its therapeutic specificity.
methodsA multi-omics approach integrating single-cell RNA sequencing (scRNA-seq), spatial transcriptomics, and structure-based docking plus normal-mode analysis was employed. Spatial domain analysis identified puerarin-responsive malignant cell clusters, while molecular docking and protein-ligand simulations prioritized CD44 as a candidate receptor. Functional validation included extracellular matrix (ECM) signaling pathway analysis, spatial colocalization studies, and in vitro experiments.
resultsSpatial analysis showed enrichment of puerarin-related signals in malignant-cell-dominated domains. ECM ligands (collagens, fibronectin, laminins) that signal through CD44/SDC1 were concentrated in these domains, where CD44 was overexpressed relative to surrounding compartments. Molecular modeling suggested CD44, a cell-surface receptor overexpressed in melanoma cells, as a putative mediator of puerarin's effects on these pathways. In vitro experiments further supported CD44's role in modulating puerarin-responsive domains.
conclusionThese observations are hypothesis-generating and provide a potential direction for future research on whether CD44 mediates puerarin's spatial effects in melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.